Prof Dorien Peters Joins Mironid’s SAB
March 26, 2018
March 26, 2018 – Mironid is delighted to announce the appointment of Prof Dorien Peters to our Scientific Advisory Board Prof. Dr. Dorien Peters is
March 26, 2018 – Mironid is delighted to announce the appointment of Prof Dorien Peters to our Scientific Advisory Board Prof. Dr. Dorien Peters is
Bowel Cancer UK and Beating Bowel Cancer announced as Edinburgh Molecular (EM) Imaging’s Charity partner. 21 March 2018 – EM Imaging, based in Edinburgh, is
An excerpt for an article written by Morgan Eichensehr, originally published in the Baltimore Business Journal March 16, 2018 – Harpoon Medical Inc.’s $100 million
March 5, 2018 – Mironid is delighted to announce the appointment of Dr Steve Felstead as Chief Medical Officer (CMO) Dr Felstead retired from the
Data supports biologic activity of APL-2 in reducing the growth rate of geographic atrophy CRESTWOOD, Ky. and CAMBRIDGE, Mass., Feb. 22, 2018 – Apellis Pharmaceuticals,
Funding for Collaborative Research Center (CRC) 841 at University Medical Center Hamburg-Eppendorf (UKE) extended for 4 years in the amount of nearly EUR 15 million.
January 15, 2018 – Mironid is delighted to announce the appointment of Dr Enno Klussmann to our Scientific Advisory Board Dr. Klussmann is currently a
CRESTWOOD, Ky. and CAMBRIDGE, Ma., Dec. 20, 2017- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to
LOUISVILLE, Ky. and CAMBRIDGE Mass., Dec. 08, 2017 – Apellis Pharmaceuticals,Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company developing a platform of novel therapeutic compounds for the
Acquisition Marks Further Success for the Epidarex Portfolio Bethesda, Md., December 7, 2017 – Epidarex Capital (“Epidarex”), an early-stage, transatlantic life science venture fund, today